• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Opaleye Management Inc. bought $28,161 worth of shares (10,000 units at $2.82) (SEC Form 4)

    7/31/25 4:05:07 PM ET
    $CDXS
    Major Chemicals
    Industrials
    Get the next $CDXS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Opaleye Management Inc.

    (Last) (First) (Middle)
    ONE BOSTON PLACE, 26TH FLOOR

    (Street)
    BOSTON MA 02108

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CODEXIS, INC. [ CDXS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/29/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.001 per share 07/29/2025 P 8,422 A $2.82 12,458,422 I By Opaleye, L.P.(1)(3)
    Common Stock, par value $0.001 per share 07/30/2025 P 1,578 A $2.795 12,460,000 I By Opaleye, L.P.(1)(3)
    Common Stock, par value $0.001 per share 250,000 I By Managed Account(2)(3)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
    2. Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
    3. Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    Opaleye Management Inc., By: /s/ James Silverman, President 07/31/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CDXS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDXS

    DatePrice TargetRatingAnalyst
    8/19/2024Buy → Hold
    The Benchmark Company
    6/3/2024$5.00Buy
    Jefferies
    5/30/2024$11.00Overweight
    Cantor Fitzgerald
    2/29/2024Hold → Buy
    The Benchmark Company
    11/7/2023Buy → Hold
    The Benchmark Company
    8/7/2023$21.00 → $4.00Outperform → Market Perform
    TD Cowen
    5/9/2023Buy → Neutral
    H.C. Wainwright
    3/31/2022$35.00Overweight
    Piper Sandler
    More analyst ratings

    $CDXS
    SEC Filings

    View All

    SEC Form 10-Q filed by Codexis Inc.

    10-Q - CODEXIS, INC. (0001200375) (Filer)

    5/7/26 4:20:56 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - CODEXIS, INC. (0001200375) (Filer)

    5/7/26 4:15:37 PM ET
    $CDXS
    Major Chemicals
    Industrials

    SEC Form DEFA14A filed by Codexis Inc.

    DEFA14A - CODEXIS, INC. (0001200375) (Filer)

    4/28/26 4:10:09 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Lutz Stefan sold $6,641 worth of shares (5,862 units at $1.13), decreasing direct ownership by 4% to 130,421 units (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    2/25/26 7:54:29 PM ET
    $CDXS
    Major Chemicals
    Industrials

    SEC Form 4 filed by President and CEO Moore Alison

    4 - CODEXIS, INC. (0001200375) (Issuer)

    2/25/26 7:53:47 PM ET
    $CDXS
    Major Chemicals
    Industrials

    SEC Form 4 filed by Officer Erbez Georgia

    4 - CODEXIS, INC. (0001200375) (Issuer)

    2/25/26 7:53:07 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Codexis downgraded by The Benchmark Company

    The Benchmark Company downgraded Codexis from Buy to Hold

    8/19/24 8:50:44 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Jefferies resumed coverage on Codexis with a new price target

    Jefferies resumed coverage of Codexis with a rating of Buy and set a new price target of $5.00

    6/3/24 8:45:11 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Cantor Fitzgerald initiated coverage on Codexis with a new price target

    Cantor Fitzgerald initiated coverage of Codexis with a rating of Overweight and set a new price target of $11.00

    5/30/24 7:33:26 AM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $227,921 worth of shares (85,000 units at $2.68) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    8/4/25 4:38:06 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Large owner Opaleye Management Inc. bought $28,161 worth of shares (10,000 units at $2.82) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    7/31/25 4:05:07 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Large owner Opaleye Management Inc. bought $282,000 worth of shares (100,000 units at $2.82) (SEC Form 4)

    4 - CODEXIS, INC. (0001200375) (Issuer)

    7/22/25 4:05:11 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA

    REDWOOD CITY, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Codexis, a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, shared new advances in RNA therapeutic manufacturing at TIDES USA 2026 at the Hynes Convention Center in Boston. Through presentations and a panel discussion, the Company highlighted how its ECO Synthesis® Manufacturing Platform is advancing the production of siRNA, now enabling stereochemical control while addressing key industry challenges in scalability and sustainability. At the conference, Codexis presented new data demonstrating, for the first time, full-length siRNA synthesis with precise control

    5/20/26 9:00:00 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis Reports First Quarter 2026 Financial Results

    Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities REDWOOD CITY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. "Next week Codexis will present new data at the TIDES USA annual meeting demonstrating how the ECO Synthesis® Manufacturing Platform enables control over phos

    5/7/26 4:05:00 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis to share RNA manufacturing advances at TIDES USA

    REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present new data on ECO Synthesis® Manufacturing Platform and provide an update on regulatory engagement for its enzymatic platform at TIDES USA, held May 11–14 at the Hynes Convention Center in Boston. As RNAi therapies expand into larger indications, manufacturing scalability, maintaining process control and delivering high-quality product is critical. Codexis will present data demonstrating advances in controlling phosphorothioate stereochemistry, improved ligation efficiency and process performance, a

    4/29/26 9:00:00 AM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Financials

    Live finance-specific insights

    View All

    Codexis Reports First Quarter 2026 Financial Results

    Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities REDWOOD CITY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. "Next week Codexis will present new data at the TIDES USA annual meeting demonstrating how the ECO Synthesis® Manufacturing Platform enables control over phos

    5/7/26 4:05:00 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis to Report First Quarter 2026 Financial Results on May 7

    REDWOOD CITY, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the first quarter of 2026 on Thursday, May 7, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-87

    4/23/26 9:00:00 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results

         Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. "Throughout 2025, we made significant strides in demonstrating the importance of our ECO Synthesis

    3/11/26 4:05:00 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Leadership Updates

    Live Leadership Updates

    View All

    Codexis Appoints Cynthia Collins to Board of Directors

    REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company's Board of Directors. "I am thrilled to welcome Cindy to our Board," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. "She has been at the forefront of innovation across multiple therapeutic modalities and brings a wealth of knowledge about the CDMO landscape. I look forward to her valuable guidance as we continue expanding the commercial footprint of our ECO Synthesis toolbox." Ms. Collins added,

    4/1/25 7:00:00 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

    REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Arthur Levin, PhD, to the Company's Strategic Advisory Board (SAB). Dr. Levin is a founding member of Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called antibody oligonucleotide conjugates, and currently serves on its Board of Directors. He brings three decades of experience developing oligonucleotides to Codexis as it continues to onboard customers for its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufact

    2/6/25 4:05:30 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Codexis Appoints Christos Richards to Board of Directors

    REDWOOD CITY, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Christos Richards to the Company's Board of Directors. "I am delighted to welcome Christos to our Board. His broad and deep knowledge and understanding of the life sciences industry will be invaluable as we continue the transformation of Codexis," said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. Mr. Richards added, "As a longstanding partner to the biopharmaceutical industry, I'm well aware of the potential of Codexis' proprietary technologies

    1/16/25 4:05:27 PM ET
    $CDXS
    Major Chemicals
    Industrials

    $CDXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Codexis Inc.

    SC 13G - CODEXIS, INC. (0001200375) (Subject)

    9/26/24 9:27:32 AM ET
    $CDXS
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Codexis Inc.

    SC 13G/A - CODEXIS, INC. (0001200375) (Subject)

    9/18/24 4:50:02 PM ET
    $CDXS
    Major Chemicals
    Industrials

    SEC Form SC 13G filed by Codexis Inc.

    SC 13G - CODEXIS, INC. (0001200375) (Subject)

    7/12/24 4:15:13 PM ET
    $CDXS
    Major Chemicals
    Industrials